Michael Stanley Rosol - 14 Jan 2022 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.

Role
Chief Medical Officer
Signature
/s/ Erika L. Eves for Michael S. Rosol, by power of attorney
Issuer symbol
N/A
Transactions as of
14 Jan 2022
Net transactions value
$0
Form type
4
Filing time
18 Jan 2022, 08:28:57 UTC
Previous filing
08 Mar 2022
Next filing
13 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAVB Common Stock Award $0 +7,728 +113% $0.000000 14,575 14 Jan 2022 Direct F1
holding NAVB Common Stock 6,816 14 Jan 2022 Held by 401(k) Plan
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock issued under the Amended and Restated 2014 Stock Incentive Plan in lieu of cash bonus, as elected by the Reporting Person.